Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PredictAD

Financiado

Cerrado

FROM PATIENT DATA TO PERSONALISED HEALTHCARE IN ALZHEIMER S DISEASE

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050,... ver más

30/11/2011

VTT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

TEKNOLOGIAN TUTKIMUSKESKUS VTT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-11-30 No tenemos la información de la convocatoria

0% 74% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

VTT

0.00€ | Lider

UNIVERSITY OF EASTERN FINLAN...

N.D. | Participante

GEHC

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RYC2021-031128-I Neuroimaging biomarkers in preclinical Alzheimer's disease 236K€ Cerrado

PID2020-118386RA-I00 LOCALIZACION DE CAMBIOS CEREBRALES EL LA ENFERMEDAD DE ALZHE... 33K€ Cerrado

ADDIT-CE Alzheimer's Disease Diagnostics Innovation and Translation t... 5M€ Cerrado

PDC2021-121350-I00 BIOMARCADORES PARA EL DIAGNOSTICO PRECOZ DEL DECLIVE COGNITI... 150K€ Cerrado

VPH-DARE@IT VPH Dementia Research Enabled by IT 18M€ Cerrado

VERDAD A blood based biomarker identifying early Alzheimer Disease... 3M€ Cerrado

Líder del proyecto

TEKNOLOGIAN TUTKIMUSKESKUS VTT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades. Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores